Clinical TrialsThe Phase 3 trial CAPItello-290 evaluating capivasertib (capi, Truqap) + paclitaxel in 1L triple negative breast cancer (TNBC) did not meet its dual primary endpoint of OS vs placebo + paclitaxel.
Profit MarginThe operating profit margin was 32%, reigniting investor concerns about high expenses.
Revenue GuidanceThe guidance change for Collaboration revenues was a negative surprise, but it also highlights management's view on its core business.